Navigation Links
Melanoma transcriptome reveals novel genomic alterations not seen before
Date:2/22/2010

February 23, 2010 Melanoma, the most deadly form of skin cancer, afflicts more than 50,000 people in the United States annually and the incidence rate continues to rise. In a study published online in Genome Research (www.genome.org), scientists have delved deeper than ever before into the RNA world of the melanoma tumor and identified genomic alterations that could play a role in the disease.

The latest high-throughput DNA sequencing technologies are ushering in a new era of discovery in cancer genomics that promises to reveal molecular mechanisms of the disease. Beyond cataloging the genetic mutations present in tumors, application of high-throughput sequencing to the RNA "transcriptome" can uncover other genomic alterations missed by DNA sequencing and identify potential targets for therapy.

For example, two adjacent genes can be transcribed together in a single "chimeric" RNA transcript. This RNA message is then translated into a protein with an altered or new function. In addition, rearrangements of the genome can cut and paste genes together, creating "gene fusions." These events occur in normal cells, but they also have the potential to cause disease. Recently these alterations have been detected a few tumor types, and it is very likely that more will be found in other cancers such as melanoma.

To capture the full spectrum of genomic alterations present in the expressed genes of melanoma, a team of researchers in the United States and Switzerland performed an integrative analysis of melanoma tumors using RNA sequencing and structural genomic data. The group identified 11 novel gene fusions involving several common cancer-related genes, and 12 cases of chimeric transcripts. "This is the first direct evidence for these types of genetic alterations in melanoma," said Michael Berger, a research scientist at the Broad Institute and first author of the report.

A particularly interesting finding was that a recurrent chimeric transcript was found involving the CDK2 gene, known to be required for melanoma cell proliferation. The authors suggest that the functional role of the aberrant CDK2 transcript is an attractive target of future investigation. In addition to novel gene fusions and chimeric transcripts, the research group also identified many other alterations in the melanoma tumors, including novel mutations, alternative splice variants, and expression changes.

Berger noted that this type of cancer transcriptome analysis is very appealing, as it complements common DNA-based genomic sequencing and characterization approaches to capture a more complete picture of the cancer genome. "Such studies should help reveal the cancer RNA world," added Levi Garraway, an Assistant Professor at Harvard Medical School/Dana-Farber Cancer Institute and the study's senior author, "thereby nominating many new genetic targets relevant to tumor biology and drug discovery."


'/>"/>

Contact: Peggy Calicchia
calicchi@cshl.edu
516-422-4012
Cold Spring Harbor Laboratory
Source:Eurekalert

Related biology technology :

1. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
2. Reovirus Infection of Melanoma Cells Generates Anti-Tumour Immunity
3. Melanoma Research Foundation and Seattle Cancer Care Alliance Host Educational Symposium and Reception for Melanoma Patients, Family Members and Healthcare Providers
4. Genasense(R) Triple Combination Therapy in Advanced Melanoma Presented at Chemotherapy Foundation Symposium
5. DermTech Is Issued U.S. Patent for the Early Detection, Staging and Monitoring of Melanoma
6. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
7. Fight Melanoma, With Joe Pesci and Dennis Haysbert on Monday, April 21st
8. DermTech Study on Melanoma Molecular Diagnostic to Be Presented at AACR
9. Oncolytics Biotech Inc. Announces Gene Therapy Publication on Reovirus Treatment for Melanoma
10. Independent Monitoring Board Recommends Completion of Accrual to Genasense(R) Phase 3 AGENDA Trial in Advanced Melanoma
11. Oncolytics Biotech Inc. Collaborators Present Reovirus and Melanoma Research at EORTC-NCI-AACR Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/15/2017)... , ... May 15, 2017 , ... ... and development solutions for drugs, biologics and consumer health products, today announced that ... on rare genetic diseases, to support preclinical and clinical development of TA-46, a ...
(Date:5/15/2017)... 15, 2017  IBM (NYSE: IBM ) scientists ... double-stranded DNA molecules with the potential to efficiently ... This technology complements the IBM Research,s "lab-on-a-chip" ... exosomes and which may also contain biomarkers for ... array of diamond shaped micropillars 1 to ...
(Date:5/11/2017)... May 11, 2017   BioLife Solutions , Inc. (NASDAQ: ... of proprietary clinical grade cell and tissue hypothermic storage ... "Company"), today reported operational highlights and financial results for the ... product sales reached a new high of $2.4 million in ... the same period in 2016. Revenue growth was driven by ...
(Date:5/11/2017)... ... May 11, 2017 , ... The key to unlocking the cause ... Sclerosis (MS) is a neurological disorder that can rob people of their ability to ... own brain cells. MS arises from a genetic tendency towards the disease combined with ...
Breaking Biology Technology:
(Date:4/5/2017)... KEY FINDINGS The global market ... CAGR of 25.76% during the forecast period of 2017-2025. ... for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is segmented ... The stem cell market of the product is segmented ...
(Date:3/30/2017)... The research team of The Hong Kong Polytechnic University (PolyU) ... ground breaking 3D fingerprint minutiae recovery and matching technology, pushing contactless ... use in identification, crime investigation, immigration control, security of access and ... ... A research team led by Dr Ajay Kumar ...
(Date:3/27/2017)... , March 27, 2017  Catholic Health Services ... Management Systems Society (HIMSS) Analytics for achieving Stage ... Model sm . In addition, CHS previously earned ... hospitals using an electronic medical record (EMR). ... high level of EMR usage in an outpatient ...
Breaking Biology News(10 mins):